BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Beijing Mabworks Biotech Co.\, Ltd. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Beijing Mabworks Biotech Co.\, Lt
 d.'s drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07911748-3432@assetmemo.bio
DTSTAMP:20261121T011042Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:MBS314: Phase 1/2 readout est. (NCT07911748)
DESCRIPTION:MBS314\, phase 1/2\, Multiple Myeloma.\nStudy: A Study of MBS31
 4 for Injection in Participants With Relapsed/Refractory Multiple Myeloma.
 \nEstimated primary completion: December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/mbs314#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07911748
URL:https://assetmemo.bio/drug/mbs314#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07405970-5444@assetmemo.bio
DTSTAMP:20261121T011042Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Obinutuzumab beta (Bejescin): Phase 3 readout est. (NCT07405970)
DESCRIPTION:Obinutuzumab beta (Bejescin)\, phase 3\, Systemic Lupus Erythem
 atosus.\nStudy: A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythe
 matosus\nEstimated primary completion: December 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/obinutuzumab-beta-bejescin#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07405970
URL:https://assetmemo.bio/drug/obinutuzumab-beta-bejescin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
